论文部分内容阅读
托吡酯的安全性警告因FDA的要求,最近Ortho-McNeil公司的托吡酯 (topiramate,Topamax) 处方信息中增加了可能引起少汗和高热的警告。在全球200多万例患者中进行的临床研究以及上市后的临床应用引起了人们对本品安全性的关注。使用本品患者的自发报告中出现潜在的少汗病例,其发
Topical Safety Warnings Topical Ortho-McNeil’s topiramate (Topamax) prescription information adds warnings that may cause hypo-perspiration and hyperthermia due to FDA requirements. The clinical research carried out in more than 2 million patients worldwide and the clinical application after the listing has aroused people’s concern for the safety of this product. The use of this product in patients with spontaneous reports appear less sweat cases, its hair